RAVIDASVIR

In April 2017, the MPP and Pharco Pharmaceuticals signed a licence and technology agreement for ravidasvir, an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes.

Country List
Algeria, Azerbaijan, Belarus, Djibouti, Egypt, Ethiopia, Iran, Iraq, Jordan, Kazahkstan, Lebanon, Libya, Morocco, Russia, Syrian Arab Republic, Tunisia, Ukraine, West Bank and Gaza, Yemen
This website uses cookies to ensure you get the best experience on our website. Learn More